Flucelvax Pregnancy Registry: an Observational Study on the Safety of Flucelvax Exposure in Pregnant Women and Their Offspring
Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
Price : $35 *
At a glance
- Drugs Influenza vaccine (Optaflu) (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions
- Sponsors Novartis; Seqirus
- 09 Aug 2016 Status changed from recruiting to withdrawn prior to enrolment.
- 22 Dec 2014 Planned End Date changed from 1 Dec 2020 to 1 Jun 2020 according to ClinicalTrials.gov.
- 22 Dec 2014 Planned primary completion date changed from 1 Dec 2020 to 1 Jun 2020 according to ClinicalTrials.gov